A Lifetime Prevalence of Comorbidity Between Bipolar Affective Disorder and Anxiety Disorders: A Meta-analysis of 52 Interview-based Studies of Psychiatric Population

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2015 Dec 3

PMID 26629535

Citations 35

Authors

Behrouz Nabavi

Alex J Mitchell

David Nutt

Affiliations

Soon will be listed here.

Abstract

Background: Bipolar affective disorder has a high rate of comorbidity with a multitude of psychiatric disorders and medical conditions. Among all the potential comorbidities, co-existing anxiety disorders stand out due to their high prevalence.

Aims: To determine the lifetime prevalence of comorbid anxiety disorders in bipolar affective disorder under the care of psychiatric services through systematic review and meta-analysis.

Method: Random effects meta-analyses were used to calculate the lifetime prevalence of comorbid generalised anxiety disorder, panic disorder, social anxiety disorder, specific phobia, agoraphobia, obsessive compulsive disorder and posttraumatic stress disorder in bipolar affective disorder.

Results: 52 studies were included in the meta-analysis. The rate of lifetime comorbidity was as follows: panic disorder 16.8% (95% CI 13.7-20.1), generalised anxiety disorder 14.4% (95% CI 10.8-18.3), social anxiety disorder13.3% (95% CI 10.1-16.9), post-traumatic stress disorder 10.8% (95% CI 7.3-14.9), specific phobia 10.8% (95% CI 8.2-13.7), obsessive compulsive disorder 10.7% (95% CI 8.7-13.0) and agoraphobia 7.8% (95% CI 5.2-11.0). The lifetime prevalence of any anxiety disorders in bipolar disorder was 42.7%.

Conclusions: Our results suggest a high rate of lifetime concurrent anxiety disorders in bipolar disorder. The diagnostic issues at the interface are particularly difficult because of the substantial symptom overlap. The treatment of co-existing conditions has clinically remained challenging.

Citing Articles

Untangling the complex relationship between bipolar disorder and anxiety: a comprehensive review of prevalence, prognosis, and therapy.

Wang Y, Liu J, Zhang R, Luo G, Sun D J Neural Transm (Vienna). 2025; 132(4):567-578.

PMID: 39755917 DOI: 10.1007/s00702-024-02876-x.

Matched Comparison Examining the Effect of Obesity on Clinical, Economic, and Humanistic Outcomes in Patients with Bipolar I Disorder.

Doane M, Jauregui A, Panchmatia H Adv Ther. 2024; 41(10):3807-3819.

PMID: 39115592 PMC: 11399203. DOI: 10.1007/s12325-024-02953-3.

The prevalence and associated characteristics of Bipolar Disorder diagnosis among admitted patients at three tertiary psychiatric hospitals in Zimbabwe: A cross sectional study.

Mwamuka R, Kaiyo-Utete M, Mawoyo C, Mangezi W PLoS One. 2024; 19(1):e0290560.

PMID: 38166016 PMC: 10760812. DOI: 10.1371/journal.pone.0290560.

The impact of MDQ positivity on quality of life impairment: Does it support the hypothesis of "Dysregulation of Mood, Energy, and Social Rhythms Syndrome" (DYMERS)?.

Carta M, Kalcev G, Scano A, Gonzalez C, Ouali U, Pinna S J Public Health Res. 2023; 12(4):22799036231208356.

PMID: 37927350 PMC: 10625312. DOI: 10.1177/22799036231208356.

Does Screening for Bipolar Disorders Identify a "Dysregulation of Mood, Energy, and Social Rhythms Syndrome" (DYMERS)? A Heuristic Working Hypothesis.

Carta M, Kalcev G, Fornaro M, Pinna S, Gonzalez C, Nardi A J Clin Med. 2023; 12(15).

PMID: 37568562 PMC: 10419483. DOI: 10.3390/jcm12155162.

References

Mantere O, Isometsa E, Ketokivi M, Kiviruusu O, Suominen K, Valtonen H . A prospective latent analyses study of psychiatric comorbidity of DSM-IV bipolar I and II disorders. Bipolar Disord. 2010; 12(3):271-84. DOI: 10.1111/j.1399-5618.2010.00810.x. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2011; 3(3):e123-30. PMC: 3090117. View

Tsai H, Lu M, Yang Y, Huang M, Yeh T, Chen W . Empirically derived subgroups of bipolar I patients with different comorbidity patterns of anxiety and substance use disorders in Han Chinese population. J Affect Disord. 2011; 136(1-2):81-89. DOI: 10.1016/j.jad.2011.08.015. View

Chang Y, Chen S, Chen S, Chu C, Lee S, Yang H . Low anxiety disorder comorbidity rate in bipolar disorders in Han Chinese in Taiwan. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 36(1):194-7. DOI: 10.1016/j.pnpbp.2011.09.013. View

Wilk J, West J, Narrow W, Marcus S, Rubio-Stipec M, Rae D . Comorbidity patterns in routine psychiatric practice: is there evidence of underdetection and underdiagnosis?. Compr Psychiatry. 2006; 47(4):258-64. DOI: 10.1016/j.comppsych.2005.08.007. View

Ciapparelli A, Paggini R, Marazziti D, Carmassi C, Bianchi M, Taponecco C . Comorbidity with axis I anxiety disorders in remitted psychotic patients 1 year after hospitalization. CNS Spectr. 2007; 12(12):913-9. DOI: 10.1017/s1092852900015704. View

Cosoff S, Hafner R . The prevalence of comorbid anxiety in schizophrenia, schizoaffective disorder and bipolar disorder. Aust N Z J Psychiatry. 1998; 32(1):67-72. DOI: 10.3109/00048679809062708. View

Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K . Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2013; 171(2):160-8. DOI: 10.1176/appi.ajp.2013.13070984. View

Azorin J, Kaladjian A, Adida M, Hantouche E, Hameg A, Lancrenon S . Psychopathological correlates of lifetime anxiety comorbidity in bipolar I patients: findings from a French national cohort. Psychopathology. 2009; 42(6):380-6. DOI: 10.1159/000241193. View

10.

Tohen M, Vieta E, Calabrese J, Ketter T, Sachs G, Bowden C . Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003; 60(11):1079-88. DOI: 10.1001/archpsyc.60.11.1079. View

11.

Frank E, Kupfer D, Thase M, Mallinger A, Swartz H, Fagiolini A . Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005; 62(9):996-1004. DOI: 10.1001/archpsyc.62.9.996. View

12.

Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J . Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2013; 171(2):169-77. DOI: 10.1176/appi.ajp.2013.13070985. View

13.

Tolin D, Frost R, Steketee G, Gray K, Fitch K . The economic and social burden of compulsive hoarding. Psychiatry Res. 2008; 160(2):200-11. PMC: 3018686. DOI: 10.1016/j.psychres.2007.08.008. View

14.

Duffy A, Alda M, Hajek T, Sherry S, Grof P . Early stages in the development of bipolar disorder. J Affect Disord. 2009; 121(1-2):127-35. DOI: 10.1016/j.jad.2009.05.022. View

15.

Altindag A, Yanik M, Nebioglu M . The comorbidity of anxiety disorders in bipolar I patients: prevalence and clinical correlates. Isr J Psychiatry Relat Sci. 2006; 43(1):10-5. View

16.

Chen Y, Dilsaver S . Comorbidity of panic disorder in bipolar illness: evidence from the Epidemiologic Catchment Area Survey. Am J Psychiatry. 1995; 152(2):280-2. DOI: 10.1176/ajp.152.2.280. View

17.

Calabrese J, Keck Jr P, Macfadden W, Minkwitz M, Ketter T, Weisler R . A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162(7):1351-60. DOI: 10.1176/appi.ajp.162.7.1351. View

18.

Wagner K . Bipolar disorder and comorbid anxiety disorders in children and adolescents. J Clin Psychiatry. 2006; 67 Suppl 1:16-20. View

19.

Gaudiano B, Miller I . Anxiety disorder comobidity in Bipolar I Disorder: relationship to depression severity and treatment outcome. Depress Anxiety. 2005; 21(2):71-7. DOI: 10.1002/da.20053. View

20.

Strakowski S, Sax K, McElroy S, Keck Jr P, Hawkins J, West S . Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. J Clin Psychiatry. 1998; 59(9):465-71. DOI: 10.4088/jcp.v59n0905. View